The cost of GLP-1 medications varies significantly depending on where you live, what insurance you have, and whether you use brand-name or compounded formulations. We surveyed pricing across all 50 states to give you the most comprehensive cost picture available.
Brand-Name Pricing Overview
At retail pharmacy prices without insurance, brand-name semaglutide (Wegovy) costs between $1,200 and $1,500 per month nationwide. Tirzepatide (Zepbound) ranges from $1,000 to $1,200 per month. These prices are relatively consistent across states because they are set by the manufacturers, though individual pharmacy markups create some variation.
State-by-State Highlights
Our research revealed several notable patterns. States with higher costs of living, particularly in the Northeast and Pacific Coast, tend to have slightly higher retail prices. States with more competitive pharmacy markets, including Texas, Florida, and Ohio, often have slightly lower retail prices due to pharmacy discount programs.
The most significant state-level variation occurs in insurance coverage. States that have mandated coverage for anti-obesity medications in their insurance regulations offer substantially better access. Currently, about 12 states have some form of mandate requiring commercial insurers to cover FDA-approved weight management medications.
Compounded Medication Pricing
Compounded semaglutide prices show much greater variation, ranging from $150 to $500 per month depending on the pharmacy, dose, and geographic location. Online telehealth providers that include compounded medication in their program fees typically charge between $200 and $400 per month for the combined service and medication.
Most Affordable States
Based on our analysis, the most affordable states for GLP-1 treatment are those with strong insurance mandates, competitive pharmacy markets, and active state Medicaid coverage. Minnesota, Massachusetts, New York, and California rank among the most accessible. These states combine insurance mandates with broader Medicaid coverage for anti-obesity medications.
Most Expensive States
States without insurance mandates and limited Medicaid coverage rank as the most expensive for out-of-pocket GLP-1 treatment. Several Southern states, where obesity rates are highest, paradoxically have some of the least accessible coverage. This creates a troubling disparity where the populations most in need of treatment face the greatest financial barriers.
Cost-Saving Strategies
Regardless of your state, several strategies can reduce your GLP-1 costs:
- Check manufacturer savings programs from Novo Nordisk and Eli Lilly, which can reduce costs by $200-$500 per month for eligible patients
- Compare prices across pharmacies using GoodRx or similar tools, as prices can vary by 20-30% within the same city
- Ask your prescriber about prior authorization for insurance coverage, even if initial coverage was denied
- Consider Canadian pharmacies for brand-name medications, where prices are 30-50% lower, though importation legality is complex
- Explore clinical trials, which often provide medication at no cost
For an up-to-date pricing comparison across telehealth providers, a comprehensive comparison of 29+ providers is available at GLP-1 Watchdog, which tracks pricing changes monthly.
The Future of GLP-1 Pricing
Several factors suggest that GLP-1 medication costs will decrease over the next two to three years. Increased manufacturing capacity from both Novo Nordisk and Eli Lilly, the entry of new competitors into the market, potential biosimilar development, and growing political pressure on drug pricing all point toward more affordable access. The launch of the Medicare bridge program in July 2026 will also significantly impact pricing dynamics for older adults.